Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Totipro Postbiotics PE0401
- Development stage
- Unknown
- Lead developer
- Glac Biotech
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Totipro Postbiotics PE0401 is a mixed postbiotic ingredient developed by Glac Biotech Co., Ltd. It is a lactic acid bacteria fermentate produced by fermenting, heating, and drying four specific probiotic strains: *Lactobacillus salivarius* AP-32, *Lactobacillus plantarum* LPL28, *Bifidobacterium longum* BLI-02, and *Lactobacillus acidophilus* TYCA06. As a postbiotic, it consists of non-viable microorganisms and their metabolic byproducts rather than live bacteria. The ingredient is designed to improve intestinal health and support the immune system by modulating the gut microbiome, reducing oxidative stress, and enhancing the intestinal barrier through the upregulation of tight junction proteins such as ZO-1, ZO-2, Occludin, JAM-A, and Claudin. It is marketed as a health functional food ingredient for conditions including chronic inflammatory bowel disease (IBD), constipation, bloating, and diarrhea. Totipro Postbiotics PE0401 was recognized with the NutraIngredients Asia Award 2023 in the Microbiome Modulation category.
- Brand names
- Totipro Postbiotics PE0401Totipro
- Other names
- postbiotics PE0401Totipro PE0401
02
Targets
ZO-2 (Tight junction protein ZO-2)CLDN (Claudin)TJP1 (Tight junction protein 1 (ZO-1))OCLN (Occludin)JAM-A (Junctional adhesion molecule A)
Beyond the preview
Go deeper on Totipro Postbiotics PE0401.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Totipro Postbiotics PE0401.